Cargando…
Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis
Cryptococcus neoformans is an encapsulated yeast responsible for approximately a quarter of a million deaths worldwide annually despite therapy, and upwards of 11% of HIV/AIDS-related deaths, rivaling the impact of tuberculosis and malaria. However, the most effective antifungal agent, amphotericin...
Autores principales: | Lu, R., Hollingsworth, C., Qiu, J., Wang, A., Hughes, E., Xin, X., Konrath, K. M., Elsegeiny, W., Park, Yoon-Dong, Atakulu, L., Craft, J. C., Tramont, E. C., Mannino, R., Williamson, P. R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538785/ https://www.ncbi.nlm.nih.gov/pubmed/31138748 http://dx.doi.org/10.1128/mBio.00724-19 |
Ejemplares similares
-
869. Oral Encochleated Amphotericin B for Cryptococcal Meningitis: a Phase II Randomized Trial
por: Atukunda, Mucunguzi, et al.
Publicado: (2022) -
Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?
por: Aigner, Maria, et al.
Publicado: (2020) -
LB1580. Efficacy Assessment of MAT2203 Encochleated Oral Formulation of Amphotericin B, in the Neutropenic Mouse Model of Pulmonary Mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2022) -
Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis
por: Stott, Katharine E, et al.
Publicado: (2022) -
Chemokine receptor CXCR3 is required for lethal brain pathology but not pathogen clearance during cryptococcal meningoencephalitis
por: Xu, Jintao, et al.
Publicado: (2020)